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Background/aim: Osteosarcoma is the most common primary bone malignancy that occurs frequently in children and adolescents.
Baicalein, a flavonoid that has attracted great attention in recent years with its strong antitumor activity, shows a wide range of biological
and pharmaceutical effects.MicroRNAs have been found to be involved in many critical processes in cancers. This study aimed to
investigate the effect of baicalein and miR-25 on Wnt/β-catenin signaling pathway of osteosarcoma cell line Saos-2.
Materials and methods: Cell viability was assessed, and qRT-PCR and Western blot were performed to study the effects of baicalein on
expression of Wnt/β-catenin signaling pathway-realted genes (β-catenin, GSK-3β, and Axin2) of Saos-2 cells.
Results: Our results indicated that baicalein can inhibit the proliferation (IC50 value 35 µM), regulate Wnt/β-catenin pathway and also
increase miR-25 expression of Saos-2. Baicalein and also miR-25 decreased the expression of β-catenin and Axin2, while increasing
the expression of GSK-3β. Down regulation of miR-25 decreased the expression of GSK-3β, while β-catenin and Axin2 expression
increased.
Conclusion: These findings demonstrate that baicalein may target genes related to the Wnt/β-catenin pathway by regulating miR-25
expression and may be a potential Wnt/β-catenin pathway inhibitor for osteosarcoma therapy.
Keywords: MicroRNA, miR-25, baicalein, osteosarcoma, Wnt/β-catenin pathway, gene expression

1. Introduction
Osteosarcoma (OS) is the widespread primary bone
malignancy that occurs generally in children and
adolescents [1], but can also occur at any age. The effective
treatment of some natural chemicals used traditionally for
human diseases is striking. Researchers have focused on the
ability of natural components to regulate signal pathways
[2]. Scutellaria baicalensis is a widely used plant because
of its strong anticancer effects. The main components of
Scutellaria are bioactive flavones which are baicalein,
baicalin, and wogonin. These phytochemicals have been
demonstrated by studies that suppress tumor growth [3,4].
Baicalein is a flavonoid that is extracted from the roots
of Scutellaria baicalensis [5]. It shows a wide variety of
biological and pharmaceutical effects and has accumulated
interest in recent years due to its potent antitumor activity.
Baicalein has been shown to exert antitumor effects by
suppressing metastasis [6] and inducing apoptosis [5, 7] in
many types of cancer.
MicroRNAs (miRNAs, miRs) are 18-25-nucleotide
length single-stranded noncoding RNAs that are critical

for various biological processes [8, 9]. The microRNA
nucleotide sequences can partially or completely bind
to the 3ʹ-untranslated regions (3ʹ-UTR) of the targeted
mRNAs to suppress gene expression [10]. Because of
these properties, a single microRNA has many target
genes. Generally, many of these targets are associated with
various signal pathways such as Notch, MAPK, PI3K/
Akt, Wnt and Jun/FOS in osteosarcoma [9] and every
stage of proliferation, differentiation, and apoptosis of
cells [7,11]. Irregularities in the expression of miRNAs are
associated with cancers [12], autoimmune disorders [13],
developmental and neurological disorders [14].
MicroRNA-25 (miR-25) is one of the microRNAs
associated with several human diseases such as cancer
[15,16]. It is involved in the development and the
progression of cancers [17]. The expression of miR-25 is
low in colon cancer tissues and inhibits cell proliferation
and migration. It means miR-25 may function as a tumor
suppressor in colon cancer [18]. Studies have shown that
microRNA-25 has high expression in various human
malignant solid tumors such as stomach [19], prostate [20]
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and liver [21]. In such cancers, miR-25 acts as an oncogene
and poses potential proliferative, antiapoptotic and cell
cycle stimuli. The effects of miR-25 on cancer are complex
because it may therefore function as an oncogenic or
tumor suppressor in different types of cancer.
Wnt signaling pathways play an important role in the
regulation of different processes such as cell proliferation,
migration, determination of cell flux, and self-renewal
of stem cells [22]. Abnormal activation of Wnt signaling
pathways leads to the emergence of many cancers [23].
There are studies supporting miRNAs that regulate Wnt
signaling components are associated with various cancers
[24]. It has been noted that miR-25 plays an important role
in the Wnt signaling pathway [17,25]. Oncogenesis due to
abnormal miRNA expression can occur through resulting
overexpression of oncogenic miRNAs or genetic loss of
tumor suppressor miRNAs [24]. Studies have shown that
Wnt/β-catenin signaling pathway activation is common in
OS cells and that abnormal activation plays an important
role in tumorigenesis and chemotherapeutic responses
[26].
There is no study showing the effect of baicalein on
miR-25 in osteosarcoma. This study aimed to investigate
the effect of baicalein and miR-25 on Wnt/β-catenin
signaling pathway of osteosarcoma cell line Saos-2.
In this study, we report the effects of baicalein on cell
proliferation in the osteosarcoma cell line Saos-2, as well
as on the expression of miR-25 and Wnt/β-catenin signal
pathway-related genes, all of which were investigated. This
study shows that baicalein acts on miR-25 to regulate the
Wnt/β-catenin signalling pathway. Besides, we present
that there is a correlation between miR-25 expression and
Wnt/β-catenin signaling pathway-related genes.
2. Materials and methods
The study designed to determine the effect of Baicalein on
miR-25 expression, as well as the effect of baicalein and
miR-25 on the Wnt/β-catenin signaling pathway-related
genes in osteosarcoma cell line Saos-2.
2.1. Cell culture
The Saos-2 cell line (Saos-2/An1, 02111901) was obtained
from ŞAP Institute (Republic of Turkey Ministry of Food
Agriculture and Livestock, Ankara, Turkey). Cells were
plated in 25 cm2 or 10 cm2 tissue culture dishes in Mc Coy’s
5A medium (supplemented with 15% FBS, 1% pen/strep).
Cells were grown at 37 °C under humidified 5% CO2–95%
air at one atmosphere. Cells were allowed to grow until
80% confluence.
2.2. Cell viability assay
Cell viability was quantified using the Muse™ Cell Analyzer
with the Muse™ Count and Viability Kit (Merck-Millipore,
Burlington, MA, USA) according to the manufacturer.
Saos-2 cells were plated onto 12-well plates (2 × 105 cells/

well) and allowed to grow for 24 h. Then, cells were severally
treated with baicalein concentrations (0, 4, 10, 15, 20, 35,
50 and 80 μM) for 48 h. Treated cells with baicalein were
suspended in PBS. Then, a working solution was added
to the cell suspension and incubated for 5 min at room
temperature in the dark. Cell viability was determined as
percent viability compared with the control samples.
2.3. Cell transfection assay
Lipofectamine 2000 (Invitrogen) was used to perform cell
transfection. Before transfection, Saos-2 cells were cultured
in Mc Coy’s 5A medium overnight. For miR-25 expression
analysis, Saos-2 cells were transfected with miR-25 mimic
(5 nM) and mimic negative control or miR-25 inhibitor
(30 nM) and inhibitor negative control according to
the manufacturer’s protocol. MiR-25 mimic group cells
were transfected with synthetic hsa-miR-25 (mirVana™
miRNA mimic); mimic control group transfected with
hsa-miR-25 mimic negative control (mirVana™ miRNA
mimic negative control #1); inhibitor group transfected
with synthetic anti-miR-25 (mirVana™ miRNA inhibitor);
inhibitor control group transfected with anti-miR-25
negative control (mirVana™ miRNA negative control).
Then, 250 μl of miR/lipofectamine compound was added
to Opti-MEM culture media and incubated for 8 h. After
incubation, the transfection medium (Opti-MEM) for
anti-miR-25 was replaced by fresh Mc Coy’s 5A medium
supplemented with or without baicalein (35 µM) to see
baicalein’s effect. Also the transfection media for miR-25
mimic, miR-25 mimic negative control and anti-miR-25
negative control was replaced by fresh Mc Coy’s 5A
medium supplemented without baicalein. Following this,
Saos-2 cells were cultured for 48 h prior to the subsequent
assays. Cells were collected and lysed in order to extract
total RNA and protein for other analyses.
2.4. Quantitative real-time PCR (qRT-PCR)
Total RNA was extracted using the TRIzol® Reagent
(Thermo Fisher Scientific Inc., Waltham, MA, USA)
according to the manufacturer’s instructions. cDNA
was reverse-transcribed using the TaqMan® Reverse
Transcription Reagents (Applied Biosystems, Waltham,
MA, USA) and was amplified by SYBR® Green PCR Master
Mix (Applied Biosystems, Waltham, MA, USA). qRT-PCR
was prepared following the instructions. Each sample
was analysed using a StepOne™Real-Time PCR System
(Thermo Fisher Scientific Inc., Waltham, MA, USA). Gene
copy number data was analysed in accordance with the
2-ΔΔCt method [27] relative to the expression of GAPDH
and compared with the control. Primers sequences for
specific genes were as follows:
β-catenin
forward
5’-TTCTGGTGCCACTACCACAGC-3’,
reverse
5’-TGCATGCCCTCATCTAATGTC-3’;
Axin2
forward 5’-GAATGAAGAAGAGGAGTG-3’, reverse
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5’-AAGACATAGCCAGAACC-3’; GAPDH forward
5’-TGCACCACCAACTGCTTAGC-3’,
reverse
5’-GGCATGGACTGTGGTCATGAG-3’.
2.5. MicroRNA quantification by qRT-PCR
MiR-25 expression levels quantification using the TaqMan
microRNA assays was performed to the manufacturer’s
instructions. cDNA was reverse transcribed from total
RNA using specific miR-25 primers (Applied Biosystems,
Waltham, MA, USA). PCR products were amplified from
cDNA samples using the TaqMan MicroRNA Assays
and Universal PCR Master Mix II (Applied Biosystems,
Waltham, MA, USA). The real-time PCR results were
normalized against an endogenous control RNU6B
(Applied Biosystems, Waltham, MA, USA).
2.6. Western blot assay
Saos-2 cells were separately treated baicalein (35 μM)
with or without miR-25 inhibitor (30 nM), miR-25 mimic
(5 nM) and their negative controls for 48 h. Total of 2 ×
106 (for baicalein treatment) or 2 × 105 (for transfection)
cells of each group were suspended in ice-cold lysis and
centrifuged at 10000 g at 4oC for 20 min. Protein solutions
from cells were collected, and protein concentration in the
resulting lysate was determined using the Bradford assay.
Each sample was separated by SDS-PAGE and transferred
onto the polyvinylidene fluoride membranes (Millipore,
USA). The membranes were subsequently blocked in
skim milk [5% in Tris-buffer with Tween® 20; (TBST
buffer)] at 25°C for 1 h. Then membranes incubated at 4
°C overnight with antibodies against β-catenin, Axin2,
GSK-3β, GAPDH (Cell Signaling Technology, Danvers,
MA, USA) or Actin (Santa Cruz Biotechnology, Inc.,
Dallas, TX, USA) in TBST containing 5% defatted milk
separately. The membranes were then incubated with
proper antirabbit IgG AP-linked secondary antibody
(Cell Signaling Technology, Danvers, MA, USA) for 1 h at
room temperature. Finally, the bands were detected with
BCIP/NBT Alkaline Phosphates Colour Development Kit
(Thermo Fisher Scientific Inc., Waltham, MA, USA) and
analyzed for optical density using NIH ImageJ software.
2.7. Statistical analysis
Statistical analyses were performed using the SPSS 20.0
software (IBM Corp., Armonk, NY, USA). Comparisons
between the 2 groups were analyzed using the Student’s
t-test. Statistical significance was considered as P < 0.05.
3. Results
3.1. The effect of baicalein on Saos-2 cell proliferation
The proliferation of Saos-2 osteosarcoma cells treated with
different concentrations of baicalein was determined by
Muse™ Count & Viability Assay. After 48 h of treatment
with baicalein, the proliferation of Saos-2 cells was
compared with the untreated group (control). We found a
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statistically significant decrease in the proliferation of cells
depending on concentrations (P < 0.05) (Figure 1). When
we look at the viability graph (Figure 1), we can see an
obvious decrease over 20 μM baicalein concentration. The
IC50 (50% inhibition concentration) value was calculated
about 35 μM and this concentration of baicalein was used
for subsequent gene expression studies. These findings
suggest that baicalein reduces the viability of Saos-2 cells.
3.2. Effect of baicalein on miR-25 expression
MiR-25 expression was determined by real time PCR
using 35 μM baicalein for 48 h on Saos-2 cells. The
expression level of miR-25 was compared with the control
group (without baicalein). It was observed that baicalein
statistically increased miR-25 expression (Figure 2A).
3.3. Effect of anti-miR-25 transfection on miR-25
expression
In order to determine the anti-miR-25 concentration to
be applied to suppress miR-25 expression in Saos-2 cells,
different concentrations were administered at 48 h. cDNA
was synthesized from the obtained samples and miR-25
expression was evaluated. A statistically significant decrease
of miR-25 expression was observed at 30 nM anti-miR-25
concentration. To evaluate baicalein’s effect we compared
miR-25 expressions on anti-miR-25 transfected group
and anti-miR-25 transfection + baicalein treated group
against to anti-miR-25 negative control group. When we
compared miR-25 expressions, we found that anti-miR-25
transfected cells were not so much affected by baicalein
treatment. MiR-25 expression wasdown regulated in both
groups (Figure 2B).
3.4. Effect of MiR-25 mimic transfection on miR-25
expression
Based on the doses recommended by the manufacturer,
it was decided that the 5 nM miR-25 mimic dose was

Figure 1. The cellular viability of Saos-2 cells. The values represent
a mean ± standard deviation of 3 independent experiments
performed in triplicate (*P < 0.05 **P < 0.01 and ***P < 0.001).
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sufficient to be used to increase the miR-25 level in the cell.
After miR-25 mimic transfection to the Saos-2 cells, miR25 expression was determined by qRT-PCR. It has been
observed that 5 nM miR-25 mimic was increased the miR25 expression (Figure 2C).
3.5. qRT-PCR results
To determine the expression levels of Wnt/β-catenin
pathway-related genes (β-catenin and Axin2), Saos-2
cells were treated with baicalein, anti-miR-25, miR-25
mimic, and their controls. When baicalein treatment was
compared with its control in Saos-2 cells, it was observed
that the β-catenin expression was downregulated (Figure
3A). Beta-catenin expression in anti-miR-25 and antimiR-25 + 35 μMbaicalein groups were compared with the
anti-miR-25 negative control group (Figure 3B). β-catenin
expression was increased in anti-miR-25 transfected cells
(with or without baicalein). When gene expression results
obtained after 5 nM miR-25-mimic transfection in Saos-

2 cells were compared with the miR-25-mimic negative
control group, it was observed that there was a significant
decrease in the expression of β-catenin mRNA (Figure
3C).
As a result of baicalein treatment to Saos-2 cells, Axin2
mRNA expression was evaluated. When this was compared
with the control group, Axin2 expression showed a
decrease (Figure 4A). Anti-miR-25 and anti-miR-25 with
35 μM baicalein treatments to Saos-2 cells were performed
to determine the Axin2 expression change and the results
were compared with the anti-miR-25 negative control
group. A statistically significant increase in the Axin2
expression was observed in the group treated with antimiR-25 alone and with baicalein concentration (35 μM)
(Figure 4B).
Saos-2 cells were transfected with 5 nM miR-25-mimic
and Axin2 gene expression was detected. The results
were compared with the miR-25-mimic negative control
group. The Axin2 expression was down-regulated when

Figure 2. Relative expression of miR-25 mRNA in Saos-2 cells. Saos-2 cells were treated with (A) baicalein (35 μM), (B) miR-25 inhibitor
(with or without baicalein) and (C) miR-25 mimic for 48 h. Then expressions were detected by qRT-PCR. RNU6B was used as an
endogenous control. Values represent the mean ± standard deviation of 3 independent experiments performed in triplicate. **P < 0.01;
***P < 0.001 indicated statistical significance.
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Figure 3. β-catenin mRNA in Saos-2 cells. Saos-2 cells were treated with (A) baicalein (35 μM), (B) miR-25 inhibitor (with or without
baicalein) and (C) miR-25 mimic for 48 h. Then expressions were detected by qRT-PCR. GAPDH was used as an endogenous control.
Values represent the mean ± standard deviation of 3 independent experiments performed in triplicate. *P < 0.05; **P < 0.01; ***P < 0.001
indicated statistical significance.

compared to the microRNA-25-mimic negative control
group (Figure 4C).
3.6. Western blot assay results
The change in expression of β-catenin, Axin2, and GSK3β protein was determined. When β-catenin protein
expression was assessed after administration of 35 μM
baicalein compared with the control group, it was found
to be effective in decreasing β-catenin expression (Figure
5A, P < 0.05). β-catenin protein expression changes after
anti-miR-25 transfection were determined and changes
were assessed by comparing with the anti-miR-25 negative
control group. β-catenin expression was increased in the
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groups in which anti-miR-25 was administered alone
and in combination with baicalein (Figure 5B). When
β-catenin protein expression results obtained after 5
nM miR-25-mimic transfection was compared with the
miR-25 mimic negative control group, β-catenin protein
expression was decreased (Figure 5C).
After the treatment of baicalein (35 μM), it was found
that the concentration of baicalein used in comparison
with the control group was effective in decreasing the
Axin2 expression (Figure 6A; P < 0.05). The changes in
Axin2 protein expression after anti-miR-25 transfection
are shown in Figure 6B. The results were compared with
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Figure 4. Axin2 mRNA in Saos-2 cells. Saos-2 cells were treated with (A) baicalein (35 μM), (B) miR-25 inhibitor (with or without
baicalein) and (C) miR-25 mimic for 48 h. Then expressions were detected by qRT-PCR. GAPDH was used as an endogenous control.
Values represent the mean ± standard deviation of 3 independent experiments performed in triplicate. *P < 0.05; **P < 0.01; ***P < 0.001
indicated statistical significance.

anti-miR-25 negative control group to evaluate expression
change. According to the results, there was an increase in
the expression of Axin2 in anti-miR-25 treated group with
or without baicalein (P < 0.05).Protein expression results
obtained after 5 nM miR-25-mimic transfection in Saos-2
cells Axin-2 expression were statistically reduced at 48th
h compared to the miR-25-mimic negative control group
(Figure 6C).
GSK-3β expression was increased compared to the
control group according to the data obtained from protein
expression studies to determine the effect of 35 μM
baicalein on the expression of the GSK-3β protein in Saos2 cells (Figure 7A; *P < 0.05). Changes in the expression
of GSK-3β protein after anti-miR-25 transfection
were determined. Expression change was assessed by
comparison with the anti-miR-25 negative control group.

In the groups that were treated with anti-miR-25 with or
without baicalein, reduction in GSK-3β expression was
reduced (Figure 7B). GSK-3β protein expression results
obtained after 5 nM miR-25 mimic transfection in Saos2 cells were compared with the mimic negative control
group. GSK-3β protein expression statistically increased
in this group (**P < 0.01; Figure 7C).
When the data obtained in the study are evaluated
together, qRT-PCR and western blot results are supportive
of each other. The change of expression in the Wnt/βcatenin pathway-related genes showed similar results in
both qRT-PCR and western blot assays.
4. Discussion
New approaches to disease treatment and alternative
practices are promising for treatment success baicalein
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Figure 5. The protein levels of β-catenin. Saos-2 cells treated with (A) baicalein (35 μM), (B) anti-miR-25 (with or without baicalein) and
(C) miR-25 mimic for 48 h. Then they were subjected to Western blotting to analyze the protein levels. Actin was used as an endogenous
control. **P < 0.01; ***P < 0.001 indicated statistical significance.
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Figure 6. The protein levels of Axin2. Saos-2 cells treated with (A) baicalein (35 μM), (B) anti-miR-25 (with or without baicalein) and
(C) miR-25 mimic for 48 h. Then they were subjected to Western blotting to analyze the protein levels. Actin was used as an endogenous
control. **P < 0.01; ***P < 0.001 indicated statistical significance.

has antitumor effects against various cancers, apoptosisinducing and antiproliferative properties in different cell
types [28,29]. Baicalein-mediated inhibition of proliferation
in osteosarcoma has been reported, but the molecular
mechanism of baicalein in OS is still not understood. Wnt/

β-catenin signal becomes overactivated in OS and promotes
tumor progression [30] and baicalein suppresses the viability
of osteosarcoma cells, such as MG-63, via the Wnt signaling
pathway [22]. In a study with human HEK293 cells, miRNA
regulating the canonical Wnt pathway was identified,
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Figure 7. The protein levels of GSK-3β. Saos-2 cells treated with (A) baicalein (35 μM), (B) anti-miR-25 (with or without baicalein)
and (C) miR-25 mimic for 48 h. Then they were subjected to Western blotting to analyze the protein levels. GAPDH was used as an
endogenous control. **P < 0.01; ***P < 0.001 indicated statistical significance.

including miR-25, which inhibits β-catenin by binding
the coding sequence. [25]. Our previous data showed that
baicalein affects miR-25 expression on different cell lines.
However, it is not certain whether the antitumor effect of
baicalein is related to the modulation of miR-25 expression
through the Wnt-β-catenin pathway on Saos-2.
In this study, baicalein inhibited cell proliferation in
Saos-2 cells (Figure 1). The antiproliferative and apoptotic
effect of baicalein has been shown in many studies. It has
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also been demonstrated that baicalein inhibits the growth
of T24 cells by blocking the cell cycle in the G1/S phase
[7]. In a recent study, baicalein has been shown to inhibit
the proliferation of MG-63 osteosarcoma cells and induce
apoptosis through the expression of ROS-induced BNIP3
[5]. These results indicate that the molecular targets of
baicalein in various cancers are different [28,29].
In another part of our study, the effect of baicalein on
the expression of miR-25 in Saos-2 cells and also the effect
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of altering miR-25 expression on the expression of genes in
the Wnt/β-catenin pathway were investigated. According
to our results, baicalein induces miR-25 expression on
Saos-2 cells (Figure 2A). When we look at the expression
of genes in the Wnt/β-catenin pathway after baicalein
treatment; the expression of β-catenin and Axin2 was
downregulated in both protein and mRNA levels (Figures
3A, 4A, 5A, and 6A). Β-catenin is an important molecule
in the Wnt/β-catenin signaling pathway and is important
for the activation status of the Wnt/β-catenin pathway in
the transition between the cytoplasm and the nucleus in
osteosarcoma cells [31]. Translocation of β-catenin from
cytoplasm to nucleus regulates transcription of many genes
involved in cellular processes [32]. Expressions of genes
such as β-catenin, GSK-3β, and Axin2 are targeted in Wnt
pathway studies. The change in gene expression indicates
that the pathway is active or inactive. Down-regulation of
β-catenin inactivates Wnt/β-catenin pathway. Increased
β-catenin levels can stimulate transcriptional activation
of proteins such as c-Myc, which controls the passage of
G1 to S phase in the cell cycle, leading to DNA replication
and mitosis [33]. The increased expression of β-catenin is
strongly associated with poor prognosis in breast cancer
patients. This accumulation can be due to many factors
such as β-catenin mutations, deficiencies in β-catenin
degradation complex and overexpression of Wnt ligands
[34]. Baicalein inhibits cell proliferation by targeting the
c-myc gene through the Wnt signaling pathway and induce
apoptosis on MG-63 osteosarcoma cell line. Baicalein
also decreases the expression of β-catenin [22]. Similarly,
studies with different cell lines have shown that baicalein
affects the Wnt/β-catenin pathway by targeting β-catenin
[3]. Axin2 (Axis inhibition protein 2) is a transcriptional
target of β-catenin/TCF. The Axin2 expression is thought
to be a sign of the activation of the Wnt pathway [35]. In our
study, the treatment of baicalein caused a decrease in the
expression of Axin2 (Figures 4A and 6A). This reduction
seems to be related to the decrease in the expression of
β-catenin and hence the reduction of translocation in the
nucleus. The translocation of β-catenin to the nucleus
activates the transcription of the target Wnt pathway genes
such as c-Myc, c-jun, cyclin D1 and Axin2 [36]. Ma et al.
[37] showed that baicalein can inhibit the expression of
Wnt1 and β-catenin in breast adenocarcinoma cells and
decreased both the expression of Cyclin D1 and the core
Axin2 expression at the level of transcription by dose and
time.
We also investigated the effect of baicalein on the
expression of miR-25 in Saos-2 cells and also the effect
of altering miR-25 expression on GSK-3β. We found
an increase in GSK-3β protein expression by baicalein
treatment (Figure 7A). GSK-3β is found in the cytoplasm
as part of the destruction complex which contains Axin

and adenomatous polyposis coli (APC). GSK-3β causes
rapid phosphorylation of cytoplasmic β-catenin. This
posttranslational phosphorylation by the degradation
complex of β-catenin makes the β-catenin a target for
ubiquitination and subsequent proteasomal degradation,
thus preventing nuclear accumulation of β-catenin [38].
Suzuki et al. [39] reported that Wnt/β-catenin signaling
pathway was activated by inactivation of GSK-3β in
Saos-2 cells. It was reported that the expression of Axin
protein in GSK-3β was increased after baicalein treatment
in MG-63 osteosarcoma cells [22]. This data is in parallel
with the results we have obtained. Our results suggest
that increased GSK-3β due to baicalein treatment causes
β-catenin reduction by ubiquitination and proteasomal
degradation [32].
The change in the presence, absence or amounts of
microRNAs in cells and tissues enables them to control
gene expression in a certain cellular process. One of the
best ways to understand the microRNAs is to elucidate
functional targets. This is possible by analyzing the
changes in target genes or pathways following gain or loss
of function of the specific microRNA. After we found out
the effect of baicalein on the Wnt/β-catenin pathway, we
also investigated the relationship between increased miR25 expression with baicalein treatment over this pathway.
MiR-25 expression was reduced by transferring miR-25inhibitor with baicalein (Figure 2) and was increased by
transferring miR-25 mimic without baicalein to determine
whether the miRNA-25 expression was effective in the
Wnt/β-catenin pathway by itself (Figures 2B and 2C).
Anti-miR-25 with and without baicalein treated cells
both showed increases on β-catenin and Axin2 mRNA
and protein expression (Figures 3B, 4B, 5B, and 6B) and
decreases on GSK-3β protein expression (Figure 7B). In
the case of miR-25 mimic transfection without baicalein
treatment, a decrease in mRNA and protein expressions
for β-catenin and Axin2 (Figures 3C, 4C, 5C, and 6C) and
an increase in expression of the GSK-3β protein (Figure
7C) were observed. These results show a direct effect of
miR-25 on the Wnt/β-catenin pathway.
Studies have shown that variation in the expression
of microRNAs regulates the components of the Wnt/βcatenin signaling pathway. Both miRNAs and Wnt
signaling pathways interact to regulate variety of biological
processes [24,38,40]. In a study of miRNAs involved in
the Wnt signaling pathway, it was reported that miR-25 is
involved in this pathway and inhibits the proliferation of
colon cancer cells and cause the inhibition of the Wnt/βcatenin pathway [25]. Coadministration of anti-miR-25
with baicalein and mimic transfection show that miR-25
is effective in modulating β-catenin, Axin2 and GSK-3β
expression in the regulation of the Wnt/β-catenin pathway.
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When all of the data obtained in the study are evaluated
together, it demonstrates that baicalein may inhibit cell
proliferation in Saos-2 cells. The expression of the GSK-3β
protein was increased when the mRNA and protein levels
of β-catenin and Axin2, which are located on the pathway
of Wnt/β-catenin and give information about the activity
of pathway, are decreased after administration of baicalein
at the IC50 concentration. Increased expression of GSK3β decreases the level of β-catenin in the cytoplasm and
decreases the amount of β-catenin that enters the nucleus
[38]. This reduction leads to a decrease in Axin2 protein
level and blockage of the Wnt/β-catenin pathway. The effect
of baicalein on the Wnt/β-catenin pathway seems to be
related to miR-25 expression. Increased miR-25 expression
by baicalein administration changes the expression of
β-catenin, Axin2, and GSK-3β genes, as demonstrated by
inhibitor and mimic transfections.
In conclusion, the effect on these genes shows that
miR-25 regulates the Wnt/β-catenin pathway in the Saos-2
cell line. Baicalein appears to have an anticancer effect on
the cells. Baicalein targeting the Wnt/β-catenin signaling
pathway in the Saos-2 suggests that it may be used as a
therapeutic in osteosarcoma. Also, the effect of baicalein

on the Wnt/β-catenin pathway paralleled with the miR-25
gene expression, suggests that the molecular mechanism
is related to miR-25 expression. In order to support the
study data, it is important to determine which Wnt/βcatenin signal pathway related genes are the direct target
gene of miR-25 by different procedures. In this molecular
mechanism, more detailed studies are needed to elucidate
the target genes of miR-25 and the relationship between
proliferation and apoptosis through the Wnt/β-catenin
signaling pathway.
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